Biliary Tract Cancer

👀 217 patients with FGFR 1-4 alteration ➡️2 median prior systemic therapies 🚨ORR: 29.5% (Prior Therapy ORR 10%) ➡️Pancreatic cancer: 55.6% ➡️Biliary Tract Cancer: 51.6% ➡️Breast Cancer: 31% …. And many more @OncoAlert @VivekSubbiah @OncBrothers @curecc (@DrShubhamPant)

Dr. David Ilson reviews important trials in colorectal, gastric, and biliary tract cancers from the 2023 American Society of Clinical Oncology annual meeting. https://t.co/V40oew2pPn @ILSONDavid #ASCO23 (@JWatch)

#Italian real-world evidence of #durvalumab, gemcitabine, cisplatin in advanced #biliarytractcancer #cholangiocarcinoma #CCA #BTC ⁦@LiverInt⁩ ⁦@casadei_gardini⁩ ⁦@lonardi_sara⁩ ⁦@Mom_enji⁩ ⁦@HUNIMED⁩ ⁦@HumanitasMilano⁩ https://t.co/ENsCg2QXMK (@LorenzaRimassa)

Our last paper—> Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data @LorenzaRimassa @sara_lonardi1 @Mom_enji @fedenichetti https://t.co/5aHbvCT7Bd (@casadei_gardini)

And TP53 wild type! #biliarytractcancer A new actionable target! (@cofiadeva)

@DanengLi, MD, discussed current approaches to treating biliary tract cancers, including the TOPAZ-1 study regimen of cisplatin, gemcitabine, and durvalumab. What are your thoughts on this case? #gicsm | @cityofhope https://t.co/ibhA0HJtfT https://t.co/L860Tf97dX (@TargetedOnc)

👉🏼Fantastic moderation of the GI oncology session by a great friend & fearless colleague @VanMorrisMD ! Cc @CathyEngMD 👉🏼Nice discussion on emerging options in colorectal cancer @MadhuEluri 👉🏼Amazing lecture on Hepatobiliary cancer by the biliary tract cancer global expert… https://t.co/y6p6fjQlZE (@VivekSubbiah)

Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium 2023 Las Vegas, NV US November 10, 2023 to November 11, 2023 Via @MayoMedEd (Thanks for the heads-up @MiteshBorad!) #hpbcsm #cholangiocarcinoma #biliarytractcancer #bileductcancer #gioncology https://t.co/iP2LnFZUQz (@ccadigest)

#FeatureFriday Today on #FeatureFriday, we are featuring a tweet by Dr. Milind Javle [@JavleMilind] about how the PBRM1 mutated biliary tract cancer subtypes aid in predicting sensitivity to PARP inhibitors. #MedTwitter (@4baseCare)

Now online in @Nature_NPJ: "PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system." From the team of Dr. Andreas Seeber @imed_tweets and @carisls GI Onc Precision Oncology Alliance collaboration. (@cancerassassin1)

In this #ASCO23 interview, @DrShubhamPant of @MDAndersonNews discusses the results of the #HERIZON-BTC-01 trial of #zanidatamab in previously treated #HER2-amplified #biliary tract #cancers. Listen to the conversation here! https://t.co/9j8Xvm7ds3 (@OncData)

Pembrolizumab with GC in biliary tract cancer. @bhargava611 @AnantRamaswamy https://t.co/z2CwSPWU0f (@DrVijayPatil11)

Sharing collaborative study by Dr. Andreas Seeber and @carisls👇 PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system https://t.co/cg5o8yOwf6 (@weldeiry)

Proud to participate in @benweinbergmd IIT (NAPOLI-2) for refractory biliary tract cancer! Simon stage 2 unlocked. @WCGIC @RueschCenter @SitemanCenter (@DrKatePedersen)

Devimistat is an inhibitor of tumoral mitochondrial metabolism. Mohan et al investigate the effect of devimistat in a phase 2b trial in patients with advanced #BiliaryTractCancer. https://t.co/z25fNbGAI9 @arathi_goblue @DNagrathLab @VSahaiMD (@CCR_AACR)

Glad to talk about #immunotherapy for #HCC and #CCA #biliarytractcancer at the @EORTC meeting during #WCGIC2023. However, the more than outstanding cochair of the HB Task Force is @DrAngelaLamarca! @myESMO @WCGIC @ILCAnews @HUNIMED @HumanitasMilano (@LorenzaRimassa)

@LorenzaRimassa, my outsanding #cochair for the #HepatoBiliary Task Force at @EORTC, summarising the status of check-point inhibitors in #BiliaryTractTumor and #HCC during #WCGIC2023 Always a pleasure to hear her speaking 😊 (@DrAngelaLamarca)

Phase III study of NUC-1031 + cisplatin vs gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121) by Jennifer Knox at #WCGIC2023 👉Interesting rationale, but very disappointing 👉mOS 9.2 vs 12.6 mo (control arm) & more Tox… https://t.co/dw1dL30Npf (@ArndtVogel)

Thanks to @NCCN grant. Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory #biliarytractcancer https://t.co/k1YTVB1GO0 @MayoCancerCare @UHhospitals @MiteshBorad @doctorC369 @NCCN @TaihoOncology (@Amitmahipal79)

Glad to discuss the options for #FGFR inhibition in the management of #cholangiocarcinoma #CCA #biliarytractcancer with @DrAngelaLamarca and @ArndtVogel @HUNIMED @HumanitasMilano @PeerVoice (@LorenzaRimassa)

Glad to chair with #NicolaSilvestris the #GInonCRC session at @AIOMtweet post #ASCO23. Fantastic presentations by @Mom_enji #MartaCaporale e #BrunoDaniele who managed to summarize and comment data on #gastric #pancreatic #HCC #CCA #biliarytractcancer @HUNIMED @HumanitasMilano (@LorenzaRimassa)

Antibiotics can be administered without compromising treatment efficacy in patients receiving a durvalumab-based regimen for advanced biliary tract #cancer. @ASCO @RuthHe12 @LombardiCancer https://t.co/vkM4mqsKf0 (@gastroendonews)

Prof @LorenzaRimassa at #ILCAschool Hong Kong sharing on advances in systemic treatment for biliary tract cancers @ILCAnews @StephenLChan1 @CUHKMedicine @HUNIMED (@RashidLui)

📍TTD #RETUD Metaanalysis suggests PFS serve as a surrogate for OS in advanced #BiliaryTractCancer. PFS&OS show correlation on trial/individual levels. HR<0.69 in PFS might indicate substantial OS benefit Kudos to our superb team @MacarullaTeresa @FabregatFranco @Florian_Castet (@GrupoTTD)

Zanidatamab could potentially treat HER2 positive biliary tract cancer. "It's not a curative option for our patients, but it definitely does give them long-term disease control," says our Dr. Shubham Pant. https://t.co/85c5DhK7fL @HealthDayTweets @DrShubhamPant #EndCancer (@MDAndersonNews)

'It's a whole new world in biliary tract cancer' - @rachnatshroff opens her keynote address for us @AdventHealthCFL @drzakoncology (@Dr_M_Tejani)

Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine. @DrShubhamPant @MDAndersonNews #ASCO23 #oncology https://t.co/hCLD2Q81YP (@OncLive)

Live now❗️ 🎉 Drs. Elena Elimova, Geoffrey Ku, & Shubham Pant (@DrShubhamPant) discuss the evidence supporting modern targeted strategies for the management of biliary tract cancers (#BTC) & gastroesophageal adenocarcinoma (#GEA) https://t.co/uf82egUcPd #MedEd #MedTwitter #ASCO23 (@PeerView)

Keynote 966 results 👇🏼👇🏼👇🏼 Pembro in combination with gem and cis compared to gem and cis alone for patients with advanced biliary tract cancer (KEYNOTE-966). ⁦@LancetGastroHep⁩ ⁦@rachnatshroff⁩ ⁩ ⁦⁦@FlavioRochaMD⁩ ⁦@curecc⁩ https://t.co/BgruGDgdKB (@SyedAAhmad5)

Watch the #GICancers experts during an #ASCO23 Live Virtual Symposium! Hear evidence supporting targeted strategies for biliary tract cancers (#BTC) and gastroesophageal adenocarcinoma (#GEA) from Drs. Elimova, Ku, & @DrShubhamPant tomorrow at 7:00 PM EDT! https://t.co/uf82egUcPd (@PeerView)

Zanidatamab generated responses in patients with HER2-amplified, locally advanced, unresectable or metastatic biliary tract cancer who were previously treated with gemcitabine. @DrShubhamPant @MDAndersonNews #ASCO23 #oncology https://t.co/AI03UpN2Va (@OncLive)

“These results support zanidatamab having meaningful clinical benefit and a potential as a future treatment option in HER2+ [#biliarytractcancers],” said @DrShubhamPant of @MDAndersonNews https://t.co/4dDkp0QXVq #ASCO23 @ASCO @ASCOPres (@OBRtweets)

James O’Bryan, MD and @RuthHe12 share their exciting #BiliaryTract Cancer research @LombardiCancer at #ASCO23 poster board 408. @GeorgetownHOF (@RueschCenter)

“Phase ll clinical trial of olaparib plus pembrolizumab in the treatment of patients with advanced biliary tract cancer.” Research by James O’Bryan, @ChYin89, @mnoel3232, @ReetuMukherjiMD, @MarionHartley4, @marshalj23, @RuthHe12 and others @LombardiCancer. Poster #408 #ASCO23 (@RueschCenter)

🔥Subgroup analysis of double-blind, placebo-controlled Ph 2 study of the LAT1 inhibitor nanvuranlat in biliary tract cancer 🔎 LAT1 transports neutral amino acids for cancer cell energy 🧐 Interesting concept, but only limited efficacy in BTC @myESMO @OncoAlert @EASLedu… https://t.co/v1Kf91Igxq (@ArndtVogel)

Zanidatamab demonstrated antitumor activity, including rapid and durable responses in patients with treatment-refractory HER2-positive biliary tract cancer @DrShubhamPant (@VibhaJayaraj)

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures [Jun 8, 2022] @kabir_mody et al. @MarkYarchoan @JCOPO_ASCO https://t.co/IN6UsL5jvN #hpbcsm #PrecisionMedicine (@mtmdphd)

A huge thanks to @DrShubhamPant, of @MDAndersonNews, for stopping by during #ASCO23 to chat about advances in biliary tract cancer and other solid tumors! Head to our site for more from the meeting! @ASCO #hpbcsm (@OncLive)

Congrats! 🎉 @DrShubhamPant great number of #pancreaticcancer and #biliarytractcancer (@CentralParkWMD)

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures [Jun 8, 2022] @kabir_mody et al. @MarkYarchoan @JCOPO_ASCO https://t.co/IN6UsL5jvN #hpbcsm #PrecisionMedicine (@mtmdphd)

Zanidatamab Elicits Responses in HER2-amplified Advanced Biliary Tract Cancer @DrShubhamPant @MDAndersonNews @ASCO #ASCO23 #oncology https://t.co/EGmjceI4ky (@OncLive)

➡️Biliary Tract Cancer: 51.6% ➡️Breast Cancer: 31% And many others….. @ASCO @MDAndersonNews @curecc @OncoAlert @OncBrothers @PanCAN @letswinpc @GIcancerDoc @MPishvaian @ArndtVogel @myESMO (@DrShubhamPant)